INTRODUCTION {#s1}
============

According to an estimation by GLOBOCAN, approximately 14.1 million new cancer cases, including 8.2 million deaths, occurred worldwide in 2012 \[[@R1]\]. Approximately 4,292,000 new cancer cases and 2,814,000 cancer deaths occurred in China in 2015, with lung, gastric, esophageal, and liver cancer being the most commonly diagnosed and the leading causes of death \[[@R2]\]. Risk factors for the leading causes of cancer-related deaths are tobacco consumption, overweight/obesity, physical inactivity, and infection \[[@R1]\]. Genetic factors should also be considered \[[@R3]--[@R8]\].

Human DNA repair genes maintain the integrity and stability of genomic DNA, consequently preventing carcinogenesis and influencing clinical outcomes \[[@R9], [@R10]\]. Many genes promote the diverse DNA repair pathways, including the nucleotide excision repair (NER) pathway \[[@R11]\]. The NER pathway consists of damage recognition, demarcation, dual incision, and gap filling and can repair a variety of damaged DNA \[[@R12]\]. The NER pathway is the main mechanism for the removal of DNA adducts and lesions caused by chemical adducts \[[@R13]\]. Polymorphisms of the genes from the NER pathway might activate cancer risk alteration \[[@R14]\]. As one of the eight core genes in the NER pathway, *Xeroderma pigmentosum* group G (*XPG*), which is also known as excision repair cross-complementing group 5 (ERCC5), can recognize and excise DNA lesions on the 3′ side to repair damaged DNA \[[@R15]\].

*XPG* gene polymorphisms were reported to be associated with the susceptibility of various types of cancers \[[@R16]--[@R18]\]. Thus, most of the investigations were focused on rs17655 G\>C (Asp1104His). The association between *XPG* gene rs751402 C\>T polymorphism (located at the 5′ untranslational region) and cancer risk has been investigated in several studies \[[@R19]--[@R40]\], but the findings were contradictory and inconclusive. Therefore, we performed this meta-analysis with all eligible publications to comprehensively evaluate the association of *XPG* gene rs751402 C\>T polymorphism with overall cancer risk.

RESULTS {#s2}
=======

Characteristics of eligible publications {#s2_1}
----------------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, 227 publications were identified from MEDLINE and EMBASE and 26 additional publications in Chinese were identified from the Chinese Biomedical (CBM) database. After reviewing the abstracts and the full texts, we excluded 222 publications and selected 31 publications with studies of the rs751402 C\>T polymorphism for further full-text review. Among these publications, nine were excluded because two studies were repetitive, five studies were clinical outcome studies, and two studies were not on cancers. In the final meta-analysis, 22 publications with studies of 10588 cases and 10511 control subjects were identified, with the duplicated samples counted only once. The characteristics of the included publications are showed in Table [1](#T1){ref-type="table"}. In these publications, sample sizes ranged from 96 to 1900 cases and from 101 to 1977 control subjects. Among the studies, 10 focused on gastric cancer \[[@R21], [@R23], [@R27], [@R29], [@R30], [@R32]--[@R34], [@R38], [@R39]\], three focused on breast cancer \[[@R25], [@R35], [@R36]\], two focused on hepatocellular carcinoma \[[@R20], [@R37]\], and one each focused on lung cancer \[[@R19]\], oral squamous cell carcinoma \[[@R22]\], salivary gland tumor \[[@R24]\], nasopharyngeal carcinoma \[[@R26]\], neuroblastoma \[[@R28]\], colorectal cancer \[[@R31]\], and prostate cancer \[[@R40]\]. Of the publications, 12 had quality scores higher than nine, and 10 had quality scores of no more than nine.

![Flowchart of the included publications](oncotarget-08-53613-g001){#F1}

###### Characteristics of the included studies in the final meta-analysis

  Name     Year   Cancer type      Region   Ethnicity   Design   Genotype method   Case   Control   MAF   HWE    Score                                     
  -------- ------ ---------------- -------- ----------- -------- ----------------- ------ --------- ----- ------ ------- ----- ----- ------ ------ ------- ----
  Shao     2007   Lung             China    Asian       HB       Taqman            433    429       105   967    448     425   110   983    0.33   0.544   11
  Yoon     2011   HCC              Taiwan   Asian       HB       Taqman            33     52        11    96     167     137   32    336    0.30   0.614   6
  Duan     2012   Gastric          China    Asian       HB       MassARRAY         172    181       47    400    206     165   29    400    0.28   0.605   11
  Zavras   2012   OSCC             Taiwan   Asian       HB       Taqman            98     110       31    239    167     137   32    336    0.30   0.614   9
  He       2013   Gastric          China    Asian       HB       Taqman            486    491       148   1125   560     499   137   1196   0.32   0.110   13
  Meng     2013   Salivary gland   China    Asian       HB       PCR-RFLP          59     63        11    133    64      55    23    142    0.36   0.065   8
  Na       2015   Breast           China    Asian       HB       PCR-RFLP          128    152       45    325    137     147   41    325    0.35   0.872   10
  Sun      2015   NPC              China    Asian       HB       PCR-LDR           17     118       237   372    19      117   235   371    0.79   0.377   11
  Chen     2016   Gastric          China    Asian       HB       Taqman            286    313       93    692    351     331   89    771    0.33   0.416   11
  He       2016   Neuroblastoma    China    Asian       HB       Taqman            96     114       38    248    208     241   82    531    0.38   0.380   10
  Feng     2016   Gastric          China    Asian       HB       PCR-RFLP          70     83        24    177    101     107   28    236    0.35   0.967   6
  Guo      2016   Gastric          China    Asian       HB       PCR-RFLP          47     73        22    142    117     136   21    274    0.32   0.029   5
  Hua      2016   Colorectal       China    Asian       HB       Taqman            792    860       248   1900   724     952   301   1977   0.39   0.680   10
  Hua      2016   Gastric          China    Asian       HB       Taqman            426    555       161   1142   433     551   189   1173   0.40   0.537   11
  Li       2016   Gastric          China    Asian       HB       PCR-RFLP          88     106       22    216    95      103   18    216    0.32   0.174   8
  Lu       2016   Gastric          China    Asian       HB       PCR-RFLP          69     91        24    184    87      97    22    206    0.34   0.510   6
  Ma       2016   Breast           China    Asian       HB       PCR-RFLP          127    150       43    320    107     101   28    236    0.33   0.580   7
  Wang     2016   Breast           China    Asian       HB       PCR-RFLP          90     10        1     101    51      39    11    101    0.30   0.398   9
  Wang     2016   HCC              China    Asian       PB       MassARRAY         70     81        18    169    232     185   60    477    0.32   0.018   12
  Yang     2016   Gastric          China    Asian       HB       PCR-RFLP          49     73        33    155    103     111   32    246    0.36   0.807   6
  Zhou     2016   Gastric          China    Asian       HB       PCR-LDR           174    196       61    431    193     193   46    432    0.33   0.827   12
  Wang     2017   Prostate         China    Asian       HB       Taqman            442    458       104   1004   477     467   111   1055   0.33   0.834   10

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; HCC, hepatocellular carcinoma; OSCC, oral squamous cell carcinoma; NPC, nasopharyngeal carcinoma; HB, hospital based; PB, population based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-LDR, polymerase chain reaction- ligase detection reaction.

Meta-analysis results {#s2_2}
---------------------

As shown in Table [2](#T2){ref-type="table"}, significant heterogeneity was presented in all genetic models. As a result, we adopted a random-effect model for all the analyses. We found the *XPG* gene rs751402 C\>T polymorphism associated with increased overall cancer risk (TT vs. CC: odds ratio \[OR\] = 1.18, 95% confidence interval \[CI\] =1.01--1.38; CT vs. CC: OR = 1.12, 95% CI = 1.01--1.24; and CT/TT vs. CC: OR = 1.12, 95% CI = 1.002--1.26). As shown in Figure [2](#F2){ref-type="fig"}, stratification analysis indicated that this polymorphism was associated with increased risk of gastric cancer (TT vs. CC: OR = 1.38, 95% CI = 1.12-1.70; CT vs. CC: OR = 1.14, 95% CI = 1.05--1.24; TT vs. CC/CT: OR = 1.27, 95% CI = 1.06-1.51; CT/TT vs. CC: OR = 1.17, 95% CI = 1.08--1.26; and T vs. C: OR = 1.17, 95% CI = 1.07--1.27) and hepatocellular carcinoma (CT vs. CC: OR = 1.61, 95% CI = 1.19--2.17; and CT/TT vs. CC: OR=1.53, 95% CI=1.10-2.13). The stratification analysis did not reveal a significant difference between the two strata in any genetic model by quality score.

###### Meta-analysis of the association between *XPG* gene rs751402 C\>T polymorphism and overall cancer risk

  Variables       No. of studies   Sample size   Homozygous                        Heterozygous                      Recessive                       Dominant                           Allele                  
  --------------- ---------------- ------------- ----------------------- --------- ----------------------- --------- ----------------------- ------- ------------------------ --------- ----------------------- ---------
  All             22               10538/10511   **1.18 (1.01--1.38)**   \<0.001   **1.12 (1.01--1.24)**   \<0.001   1.09 (0.97--1.23)       0.009   **1.12 (1.002--1.26)**   \<0.001   1.09 (1.00--1.18)       \<0.001
  Cancer type                                                                                                                                                                                                   
  Gastric         10               4664/5150     **1.38 (1.12--1.70)**   0.020     **1.14 (1.05--1.24)**   0.936     **1.27 (1.06--1.51)**   0.053   **1.17 (1.08--1.26)**    0.437     **1.17 (1.07--1.27)**   0.043
  Breast          3                746/662       0.79 (0.31--1.98)       0.010     0.64 (0.26--1.58)       \<0.001   0.87 (0.43--1.79)       0.044   0.60 (0.23--1.60)        \<0.001   0.63 (0.29--1.35)       \<0.001
  HCC             2                265/813       1.24 (0.73--2.12)       0.262     **1.61 (1.19--2.17)**   0.373     0.96 (0.62--1.49)       0.398   **1.53 (1.10--2.13)**    0.256     1.26 (0.97--1.63)       0.220
  Others          7                4863/5395     0.95 (0.78--1.16)       0.082     1.03 (0.89--1.18)       0.071     0.94 (0.82--1.07)       0.270   1.02 (0.88--1.18)        0.028     0.99 (0.90--1.10)       0.025
  Quality score                                                                                                                                                                                                 
  \>9             12               8775/9691     1.08 (0.93--1.25)       0.011     1.06 (0.98--1.17)       0.063     1.02 (0.92--1.14)       0.137   1.08 (0.98--1.19)        0.007     1.05 (0.98--1.14)       0.002
  ≤9              10               1763/2329     1.34 (0.95--1.89)       0.009     1.13 (0.86--1.48)       \<0.001   1.21 (0.90--1.62)       0.029   1.12 (0.84--1.51)        \<0.001   1.07 (0.85--1.35)       \<0.001

OR, odds ratio; CI, confidence interval; Het, heterogeneity; HCC, hepatocellular carcinoma.

![Stratification analysis for the association between *XPG* gene rs751402 C\>T polymorphism and overall cancer risk by cancer type under the dominant model (CT/TT vs. CC)\
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False-positive report probability analysis for significant findings {#s2_3}
-------------------------------------------------------------------

We performed false-positive report probability (FPRP) analysis for all significant findings and confirmed that the findings were significant at the priority of 0.1 for gastric cancer and hepatocellular carcinoma (Table [3](#T3){ref-type="table"}).

###### False-positive report probability analysis values for the noteworthy findings

  Genotype                   Crude OR (95% CI)    *P*^a^    Statistical power^b^   Prior probability                                       
  -------------------------- -------------------- --------- ---------------------- ------------------- ----------- ----------- ----------- -------
  Overall cancer risk                                                                                                                      
   TT vs. CC                 1.18 (1.01--1.38)    0.040     1.000                  **0.107**           0.264       0.798       0.976       0.998
   CT vs. CC                 1.12 (1.01--1.24)    0.040     1.000                  **0.106**           0.263       0.797       0.975       0.997
   CT/TT vs. CC              1.12 (1.002--1.26)   0.047     1.000                  **0.123**           0.296       0.822       0.979       0.998
  Hepatocellular carcinoma                                                                                                                 
   CT vs. CC                 1.61 (1.19--2.17)    0.002     0.394                  **0.013**           **0.038**   0.305       0.816       0.978
   CT/TT vs. CC              1.53 (1.10--2.13)    0.011     0.608                  **0.050**           **0.137**   0.636       0.946       0.994
  Gastric cancer                                                                                                                           
   TT vs. CC                 1.38 (1.12--1.70)    0.002     1.000                  **0.007**           **0.019**   **0.179**   0.687       0.956
   CT vs. CC                 1.14 (1.05--1.24)    0.003     1.000                  **0.008**           **0.024**   0.213       0.732       0.965
   TT vs. CT/CC              1.27 (1.06--1.51)    0.010     1.000                  **0.030**           **0.085**   0.506       0.912       0.990
   CT/TT vs. CC              1.17 (1.08--1.26)    \<0.001   1.000                  **0.001**           **0.002**   **0.019**   **0.161**   0.658
   T vs. C                   1.17 (1.07--1.27)    0.001     1.000                  **0.002**           **0.006**   **0.063**   0.404       0.871

OR, odds ratio; CI, confidence interval.

^a^A *χ^2^* test was used to evaluate the distributions of genotype frequency.

^b^Statistical power was calculated by use of the number of observations in the subgroup and *P* values in this table.

The genotype-based mRNA expression for *XPG* gene rs751402 C\>T polymorphism {#s2_4}
----------------------------------------------------------------------------

As shown in Table [4](#T4){ref-type="table"}, the rs751402T allele carriers were associated with decreased *XPG* mRNA expression among Asians (not significant), Africans (TT vs. CC: *P* = 0.029), and Caucasians (TT vs. CC: *P* = 0.013; and TT vs. CC/CT: *P* = 0.011), as well as all subjects (TT vs. CC: *P* = 0.010; and TT vs. CC/CT: *P* = 0.008).

###### *XPG* gene mRNA expression by the genotypes of rs751402 C\>T^a^

  Population   Genotypes   No.           Mean ± SD     *P*^b^   *P*~trend~^c^
  ------------ ----------- ------------- ------------- -------- ---------------
  Asian        CC          30            9.79 ± 0.21            0.409
  CT           47          9.76 ± 0.22   0.537                  
  TT           13          9.69 ± 0.23   0.188                  
  Dominant     60          9.75 ± 0.22   0.352                  
  Recessive    77          9.77 ± 0.22   0.233                  
  CEU          CC          54            9.72±0.23              **0.039**
  CT           29          9.70±0.22     0.823                  
  TT           7           9.48±0.15     **0.013**              
  Dominant     36          9.66±0.22     0.271                  
  Recessive    83          9.71±0.23     **0.011**              
  YRI          CC          35            9.86±0.16              0.100
  CT           43          9.82±0.17     0.245                  
  TT           12          9.75±0.14     **0.029**              
  Dominant     55          9.80±0.17     0.094                  
  Recessive    78          9.84±0.17     0.074                  
  All          CC          119           9.78 ± 0.22            **0.030**
  CT           119         9.77 ± 0.21   0.693                  
  TT           32          9.67 ± 0.21   **0.010**              
  Dominant     151         9.75 ± 0.21   0.220                  
  Recessive    238         9.77 ± 0.21   **0.008**              

^a^The rs751402 C\>T genotypes data were obtained from the HapMap Phase II Release 23 data, and *XPG* mRNA expression levels were from EBV-transformed lymphoblastoid cell lines from 270 individuals.

^b^Two-side Student's *t-*test within the stratum.

^c^*P* values for the trend test of the *XPG* gene mRNA expression among three genotypes for rs751402 C\>T from a general linear model.

Sensitivity analysis and publication bias {#s2_5}
-----------------------------------------

By omitting each publication once in every genetic model in the sensitivity analysis, we did not find any individual publication that could significantly alter the pooled ORs, which indicated that our data were stable and trustworthy. As shown in Figure [3](#F3){ref-type="fig"}, no obvious publication bias was observed for rs751402 C\>T polymorphism (TT vs. CC: *P* = 0.111; CT vs. CC: *P* = 0.251; TT vs. CT/CC: *P* = 0.236; CT/TT vs. CC: *P* = 0.249; and T vs. C: *P* = 0.298).

![Funnel plot for the association between *XPG* gene rs751402 C\>Tpolymorphism and overall cancer risk under the dominant model (CT/TT vs. CC)](oncotarget-08-53613-g003){#F3}

Trial sequential analysis {#s2_6}
-------------------------

As shown in Figure [4](#F4){ref-type="fig"}, we observed that the cumulative z-curve crossed the monitoring boundary before reaching the required sample size, indicating the sample size was sufficient and no further investigation was needed to verify the results.

![Trial sequential analysis for *XPG* gene rs751402 C\>T polymorphism under the dominant model](oncotarget-08-53613-g004){#F4}

DISCUSSION {#s3}
==========

In the current meta-analysis, we investigated all available publications that contained studies of the association between *XPG* gene rs751402 C\>T polymorphism and cancer risk. The pooled results suggest that this polymorphism is associated with increased cancer risk, especially for gastric cancer and hepatocellular carcinoma.

The *XPG* gene, which is located at 13q33 and consists of 15 exons, promotes the removal of damaged DNA in the NER process \[[@R41]\]. When DNA repair capability is decreased, cells might fail to repair the damage. As DNA mutations accumulate, carcinoma might occur \[[@R9], [@R21]\]. The *XPG* gene is an essential component of the NER pathway, and it activates the cleavage of DNA on the 3′ side of the lesion \[[@R42]\]. Studies reported that the *XPG* gene promotes cellular processes such as RNA polymerase II transcription and transcription-coupled DNA repair \[[@R43]\]. *XPG* gene polymorphisms might affect the expression or function of the XPG protein. Studies in several publications investigated the function of *XPG* gene rs751402 C\>T polymorphism in cancer susceptibility. However, inconsistent results have been reported. Duan et al. \[[@R21]\] found that this polymorphism might increase the risk of gastric cancer in a study of 403 gastric cancer cases and 403 healthy control subjects. This association was also confirmed in gastric cancer by Yang et al. \[[@R38]\] in a study of 155 gastric cancer cases and 246 healthy control subjects, in hepatocellular carcinoma by Yoon et al. \[[@R20]\], and in oral squamous cell carcinoma by Zavras et al. \[[@R22]\]. Hua et al. \[[@R31]\] found that this polymorphism might be associated with decreased colorectal cancer susceptibility by studying 1901 colorectal cases and 1976 control subjects, and might have no effect in gastric cancer, as determined by 1142 cases and 1173 control subjects. Others found that this polymorphism might have weak effects on cancer susceptibility. The controversy can possibly be ascribed to the small sample size as well as cancer differences. To overcome the limitations of a single study and to reduce the likelihood of random errors being responsible for false-positive or false-negative associations, we performed the current meta-analysis to assess the association between *XPG* gene rs751402 C\>T polymorphism and overall cancer susceptibility. We included 22 available publications, encompassing 10588 cases and 10511 control subjects, and found that this polymorphism was associated with increased overall cancer risk, especially for gastric cancer and hepatocellular carcinoma. We also performed FPRP analysis to confirm that the significant associations were trustworthy and robust. In addition, the genotype-based mRNA expression analysis as performed also indicated that this polymorphism might be associated with *XPG* gene mRNA expression alteration.

The current meta-analysis has five advantages. First, we searched the latest publications and we also included the publications written in Chinese. Second, we assessed the quality of each investigation and conducted stratification analysis by the quality score to search for publication bias. Third, we performed genotype-based mRNA expression analysis to provide further evidence that the rs751402 C\>T polymorphism can influence the expression of the *XPG* gene. Fourth, we performed FPRP analysis, which can confirm whether the significant associations are trustworthy and robust. Fifth, we performed TSA to strengthen the robustness and minimize random errors of our conclusions.

Although in the present study we performed the latest and largest meta-analysis for assessing the association between *XPG* gene rs751402 C\>T polymorphism and overall cancer susceptibility, four limitations must be considered. First, because of the heterogeneity in the current meta-analysis, the conclusions on the overall cancer risk should be interpreted cautiously. Second, the results of this study were based on the unadjusted ORs, which might suppress the final results. Third, all the study subjects were Asians. Other ethnicities are needed as subjects in future studies. Fourth, despite the adequacy of the total number of publications, the number of publications that contain studies for some cancers were inadequate. Investigations into other cancers are needed.

Our meta-analysis found that *XPG* gene rs751402 C\>T polymorphism is associated with increased overall cancer risk, especially with respect to gastric cancer and hepatocellular carcinoma. Investigations of different cancers and ethnicities are needed to validate our findings.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We systematically searched publications from the MEDLINE, EMBASE, and CBM databases (the last search was updated April 28, 2017) using the following search terms: "cancer or carcinoma or tumor or neoplasm," "excision repair cross-complementing group 5 or *ERCC5* or xeroderma pigmentosum group G or *XPG* or rs751402," and "polymorphism or variant or single nucleotide polymorphism (SNP) or variation." We also manually searched the reference lists of the articles in the included publications.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The studies in the included publications met the following criteria: (1) the study evaluated the association between *XPG* gene rs751402 C\>T polymorphism and cancer risk, (2) the study was on human beings, (3) the study was a case-control or cohort design, (4) sufficient data were provided to calculate the ORs and 95% CIs, and (5) the study was published in English or Chinese.

Exclusion criteria were (1) the study was not a case-control design, (2) the study was duplicated from previous studies, (3) articles were case reports or review articles, and (4) the studies were without detailed genotype data.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two authors (Haixia Zhou and Ting-Yan Shi) performed the publication search and data extraction independently. The extracted information includes surname of the first author, publication year, cancer type, country of origin, ethnicity, genotyping methods, and numbers of cases and control subjects with rs751402 CC, CT and TT genotypes. We assessed the quality of each publication based on the quality score assessment \[[@R44]\]. All contradictory information was discussed and resolved through consensus when necessary.

Genotype-based mRNA expression analysis {#s4_4}
---------------------------------------

To determine whether the *XPG* gene rs751402 C\>T polymorphism can influence expression of the *XPG* gene, we conducted genotype-based mRNA expression analysis as previously described \[[@R3], [@R45], [@R46]\]. Genotype data of *XPG* gene rs751402 C\>T polymorphism for 270 individuals were obtained from HapMap Phase II Release 23. The mRNA expression data for the corresponding individuals were from SNPexp \[[@R47]\].

Statistical analysis {#s4_5}
--------------------

Pooled ORs and 95% CIs were used to investigate the strength of the association between *XPG* gene rs751402 C\>T polymorphism and overall cancer risk under the homozygous (TT vs. CC), heterozygous (CT vs. CC), recessive (TT vs. CT+CC), dominant (CT+TT vs. CC), and allele contrast (T vs. C) models. A goodness-of-fit χ^2^ test was adopted to assess the Hardy-Weinberg equilibrium for the control subjects. Stratification analysis was carried out by cancer type (publications with no more than two were merged as the Others Group) and quality score (\>9 and ≤9). Heterogeneities were assessed by χ^2^-based Q test, and a fixed-effect model was adopted when *P* \> 0.1. Otherwise, the random-effect model was applied \[[@R48]\]. Sensitivity analysis was then conducted by omitting each publication in turn to evaluate the stability of the overall results. Potential publication bias was assessed by Begg's funnel plot \[[@R49]\] and Egger's linear regression test \[[@R50]\]. FPRP and TSA were as previously described \[[@R8]\]. All the statistics were two-sided, and *P* \< 0.05 was statistically significant. All statistical analyses were performed by the STATA software (Version 11.0; Stata Corporation, College Station, TX).
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